“…(1S,2R)-3: R1=H, R2=CH3 (1S,2fl)-4: R'=R2=CH3 8-Hydroxy-2-(dipropylamino)tetralin (8-OH-DPAT; 2), which was reported by Arvidsson et al5 to be a potent centrally active 5-HT-receptor agonist, is a selective 5-HTiA-receptor ligand.6-8 It has served as a lead compound in the search for compounds with similar indirect models which describe observed structureactivity relationships (SAR) have been deduced. [12][13][14][15] One of the key derivatives in our indirect model for 5-HTiA-receptor agonists13 was the potent agonist (lS,2R)-ALK-3 [(lS,2R)-3]. 16 Compound QS,2fl)-3 has a limited conformational flexibility as compared to 2, 12 and the selectivity and high 5-HTiA-receptor affinity of 2 appeared to be retained in (l,S,2R)-3.16 '17 A more detailed pharmacological evaluation has demonstrated that (lS,2R)-3 may be best characterized as a partial 5-HTiA-receptor agonist.17 Similarly, (S)-2 appears to be a partial 5-HTiA-receptor agonist, whereas (R)-2 behaves as a full agonist.17 In contrast to the enantiomers of 2, which display little stereoselectivity, 18 (lS,2R)-3 behaves as a potent 5-HTiA-receptor agonist in ex vivo biochemical and behavioral tests, whereas the l.R,2iS-enantiomer is inactive.…”